ME43

Compound and inactive control can be requested here.

overview

The nuclear NR4A receptors (nerve growth factor IB-like receptor family) are ligand-activated transcription factors with (neuro)protective properties as part of the immediate early response and have emerged as promising therapeutic targets in various pathologies including neurodegeneration. Nurr1 (NR4A2) plays a critical role in the development, function, and maintenance of dopaminergic neurons. Reduced expression of Nurr1 has been observed in both Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients, as well as in corresponding rodent models, suggesting its potential involvement in the pathogenesis and progression of these disorders.

Chemical structures of ME43 and the negative control ME113.

Based on the Nurr1-DHI complex structure, we have identified high-affinity ligands (Kd 0.08–0.12 μM) targeting the DHI binding site of Nurr1. Optimization of this ligand scaffold yielded a potent NR4A agonist ME43, characterized by favorable physicochemical properties, high selectivity, and low toxicity, making it a valuable chemical probe for studying Nurr1 activation via the DHI site. Treatment of neuronal cells with ME43 led to increased expression of Nurr1-regulated neuroprotective genes, including brain-derived neurotrophic factor (BDNF), supporting therapeutic potential of Nurr1 activation in combating neurodegenerative diseases.

Biological activity summary:

  • Binding affinity (ITC): Kd 0.12 μM to recombinant Nurr1
  • Cellular potency was determined in Gal4-NR4A hybrid reporter assays yielding the following data: EC50 (Nur77) = 0.04±0.01 µM (eff. 2.0 ± 0.1-fold); EC50 (Nurr1) = 0.06 ± 0.02 µM (eff. 1.9 ± 0.1-fold); EC50 (NOR1) = 0.07±0.03 µM (eff. 2.0 ± 0.2-fold).
  • ME43 activated full-length human Nurr1 on the response elements for the monomer (NBRE, EC50 = 0.07 ± 0.02 μM), homodimer (NurRE, EC50 = 0.027 ± 0.008 μM) and RXR heterodimer (DR5, EC50 = 0.014 ± 0.006 μM) with consistently low nanomolar potency.
  • ME43 induced neuroprotective gene expression (mRNA) in N27 cells at 1 µM.
  • ME43 is selective over nuclear receptors outside the NR4A family with moderate PXR activation at 3 μM (EC50 = 1.5 ± 0.6 μM)
     
properties
Physical and chemical properties for ME43
Molecular weight321,76
Molecular formulaC18H12ClN3O
IUPAC name5-Chloro-N-(quinolin-3-yl)-1H-indole-6-carboxamide
AlogP4.15
PSA57.78
No. of chiral centers0
No. of rotatable bonds3
No. of hydrogen bond acceptors3
No. of hydrogen bond donors2
Storage

Stable as a solid at room temperature. 

Store DMSO stock solutions (10 mM) at -20 °C. Use only 1 freeze/thaw cycle per aliquot.

DMSO stocks beyond 3-6 months or 2 freeze/thaw cycles should be tested for activity before use

DissolutionSoluble in DMSO up to 10 mM
Physical and chemical properties for ME113
Molecular weight335.79
Molecular formulaC19H14ClN3O
IUPAC name5-Chloro-N-methyl-N-(quinolin-3-yl)-1H-indole-6-carboxamide
AlogP4.18
PSA48.99
No. of chiral centers0
No. of rotatable bonds4
No. of hydrogen bond acceptors3
No. of hydrogen bond donors1
Storage

Stable as a solid at room temperature. 

Store DMSO stock solutions (10 mM) at -20 °C. Use only 1 freeze/thaw cycle per aliquot.

DMSO stocks beyond 3-6 months or 2 freeze/thaw cycles should be tested for activity before use

DissolutionSoluble in DMSO up to 10 mM

SMILES:

ME43: ClC1=C(C(NC2=CC(C=CC=C3)=C3N=C2)=O)C=C(NC=C4)C4=C1

ME113: ClC1=C(C(N(C)C2=CC(C=CC=C3)=C3N=C2)=O)C=C(NC=C4)C4=C1

InChI:

ME43: InChI=1S/C18H12ClN3O/c19-15-8-12-5-6-20-17(12)9-14(15)18(23)22-13-7-11-3-1-2-4-16(11)21-10-13/h1-10,20H,(H,22,23)

ME113: InChI=1S/C19H14ClN3O/c1-23(14-8-12-4-2-3-5-17(12)22-11-14)19(24)15-10-18-13(6-7-21-18)9-16(15)20/h2-11,21H,1H3

InChIKey:

ME43: ZJPUSKBFLQMYJU-UHFFFAOYSA-N

ME113: AUSKEAIAMTVFBX-UHFFFAOYSA-N

 

selectivity profile
in vitro potency
cell based assay data
references

Markus Egner, Romy Busch, Úrsula López-García, Max Lewandowski, Georg Höfner, Thomas Wein, Julian A. Marschner, and Daniel Merk. A Nurr1 Agonist Derived from the Natural Ligand DHI Induces Neuroprotective Gene Expression. J. Med. Chem., 2025, 68, 4829–4847.

https://doi.org/10.1021/acs.jmedchem.4c03104 

pk properties
co-crystal structures
synthetic schemes
materials and methods